Olympus expands in cancer tech with $270M buy of BioProtect

Olympus expands in cancer tech with $270M buy of BioProtect is a pharma and life sciences industry update from MedTech Dive. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

Susan Kelly · 2026-05-26

BioProtect’s balloon spacer device separates the prostate from other structures during cancer radiation.

Source: MedTech Dive